Shire-Baxalta $32B Merger Would Create Powerhouse Rare-Disease Drugmaker

Big companies used to steer clear of rare-disease drugs because there aren't enough patients to make them profitable, but that has changed as the market has sustained high prices. In other pharmaceutical news, drug companies launch a cooperative effort to fight cancer, the Supreme Court lets a ruling on deceptive marketing of an anti-psychotic drug stand, and states look at ways to combat high prices.